Swiss National Bank’s Progenics Pharmaceuticals Inc PGNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-165,500
| Closed | -$629K | – | 2571 |
|
|
2020
Q1 | $629K | Hold |
165,500
| – | – | ﹤0.01% | 2076 |
|
|
2019
Q4 | $842K | Buy |
165,500
+6,400
| +4% | +$33.9K | ﹤0.01% | 2233 |
|
|
2019
Q3 | $804K | Buy |
159,100
+5,000
| +3% | +$24.9K | ﹤0.01% | 2167 |
|
|
2019
Q2 | $951K | Hold |
154,100
| – | – | ﹤0.01% | 2140 |
|
|
2019
Q1 | $715K | Buy |
154,100
+6,700
| +5% | +$30.3K | ﹤0.01% | 2254 |
|
|
2018
Q4 | $619K | Hold |
147,400
| – | – | ﹤0.01% | 2264 |
|
|
2018
Q3 | $924K | Buy |
147,400
+25,000
| +20% | +$192K | ﹤0.01% | 2185 |
|
|
2018
Q2 | $984K | Hold |
122,400
| – | – | ﹤0.01% | 2167 |
|
|
2018
Q1 | $913K | Buy |
122,400
+6,700
| +6% | +$44.5K | ﹤0.01% | 2124 |
|
|
2017
Q4 | $688K | Hold |
115,700
| – | – | ﹤0.01% | 2305 |
|
|
2017
Q3 | $852K | Hold |
115,700
| – | – | ﹤0.01% | 2160 |
|
|
2017
Q2 | $786K | Hold |
115,700
| – | – | ﹤0.01% | 2194 |
|
|
2017
Q1 | $1.09M | Hold |
115,700
| – | – | ﹤0.01% | 1969 |
|
|
2016
Q4 | $1M | Hold |
115,700
| – | – | ﹤0.01% | 2038 |
|
|
2016
Q3 | $732K | Hold |
115,700
| – | – | ﹤0.01% | 2164 |
|
|
2016
Q2 | $488K | Hold |
115,700
| – | – | ﹤0.01% | 2367 |
|
|
2016
Q1 | $487K | Buy |
115,700
+21,200
| +22% | +$94.4K | ﹤0.01% | 2320 |
|
|
2015
Q4 | $579K | Hold |
94,500
| – | – | ﹤0.01% | 2176 |
|
|
2015
Q3 | $541K | Buy |
94,500
+11,700
| +14% | +$89.8K | ﹤0.01% | 2145 |
|
|
2015
Q2 | $618K | Buy |
+82,800
| New | +$501K | ﹤0.01% | 2106 |
|
Other funds holding PGNX
Swiss National Bank's PGNX Position: Q2 2020 in Review
Swiss National Bank sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 165,500 shares — an estimated $629K sold.
Swiss National Bank first reported a position in PGNX in Q2 2015 and held it in 20 quarters. The position peaked at $1.09M in Q1 2017. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.
- Swiss National Bank reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
- Swiss National Bank sold 165,500 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $629K.
- Swiss National Bank first reported a position in Progenics Pharmaceuticals Inc in Q2 2015 and held it in 20 quarters.
- Swiss National Bank's Progenics Pharmaceuticals Inc position peaked at $1.09M in Q1 2017.
- 3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.
Based on Swiss National Bank's 13F filing for Q2 2020, filed 5 Aug 2020.